patients who visited Apkoo-Jung Oracle Dermatology Center between August and September 2019, and received facial treatments with INCO for cosmetic purposes, including sebum control, face lifting, and pore size improvement were reviewed. Among these patients, those who had regular follow-ups at the clinic three times (after 1 week, 4 weeks, and 12 weeks) after the procedures were included. If the date of follow-up differed by more than 3 days (after 1 week or 4 weeks) or 7 days (after 12 weeks) of the scheduled date, the results for the patient were not included. This study was approved by the electronic Institutional Review Board of the Korea National Institute for Bioethics Policy (IRB no.: P01-202006-21-005).
Protocol of the Cosmetic Procedure
Each 100-U vial of INCO (Xeomin; Merz Pharmaceuticals GmbH, Hessen, Germany) was diluted using 5 ml of bacteriostatic saline. The face was cleansed with isopropyl alcohol and applied with anesthetic cream (Lidocan cream [lidocaine 96 mg/g]; Daehan Newpharm, Gyeonggi, South Korea) for 30 min before injection. The lateral face, anterior medial cheek, mandibular line, and depressor anguli oris (DAO) points were injected intradermally
Protocol of the Cosmetic Procedure
Each 100-U vial of INCO (Xeomin; Merz Pharmaceuticals GmbH, Hessen, Germany) was diluted using 5 ml of bacteriostatic saline. The face was cleansed with isopropyl alcohol and applied with anesthetic cream (Lidocan cream [lidocaine 96 mg/g]; Daehan Newpharm, Gyeonggi, South Korea) for 30 min before injection. The lateral face, anterior medial cheek, mandibular line, and depressor anguli oris (DAO) points were injected intradermally
